| Title |
Cognitive remission: a novel objective for the treatment of major depression?
|
|---|---|
| Published in |
BMC Medicine, January 2016
|
| DOI | 10.1186/s12916-016-0560-3 |
| Pubmed ID | |
| Authors |
Beatrice Bortolato, Kamilla W. Miskowiak, Cristiano A. Köhler, Michael Maes, Brisa S. Fernandes, Michael Berk, André F. Carvalho |
| Abstract |
Cognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic targets on neurocognitive dysfunction in MDD. Conventional antidepressant drugs mitigate cognitive dysfunction in some people with MDD. However, a significant proportion of MDD patients continue to experience significant cognitive impairment. Two multicenter randomized controlled trials (RCTs) reported that vortioxetine, a multimodal antidepressant, has significant precognitive effects in MDD unrelated to mood improvement. Lisdexamfetamine dimesylate was shown to alleviate executive dysfunction in an RCT of adults after full or partial remission of MDD. Preliminary evidence also indicates that erythropoietin may alleviate cognitive dysfunction in MDD. Several other novel agents may be repurposed as cognitive enhancers for MDD treatment, including minocycline, insulin, antidiabetic agents, angiotensin-converting enzyme inhibitors, S-adenosyl methionine, acetyl-L-carnitine, alpha lipoic acid, omega-3 fatty acids, melatonin, modafinil, galantamine, scopolamine, N-acetylcysteine, curcumin, statins, and coenzyme Q10. The management of cognitive dysfunction remains an unmet need in the treatment of MDD. However, it is hoped that the development of novel therapeutic targets will contribute to 'cognitive remission', which may aid functional recovery in MDD. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 423 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Spain | 1 | <1% |
| Unknown | 420 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 63 | 15% |
| Researcher | 55 | 13% |
| Student > Bachelor | 49 | 12% |
| Student > Ph. D. Student | 46 | 11% |
| Student > Doctoral Student | 22 | 5% |
| Other | 74 | 17% |
| Unknown | 114 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 88 | 21% |
| Psychology | 79 | 19% |
| Neuroscience | 37 | 9% |
| Biochemistry, Genetics and Molecular Biology | 18 | 4% |
| Nursing and Health Professions | 14 | 3% |
| Other | 52 | 12% |
| Unknown | 135 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#1,383,514
of 23,515,785 outputs
Outputs from BMC Medicine
#970
of 3,554 outputs
Outputs of similar age
#25,970
of 398,324 outputs
Outputs of similar age from BMC Medicine
#14
of 50 outputs
Altmetric has tracked 23,515,785 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,554 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 44.5. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,324 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.